Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- bjc2017177
Final published version, 268 KB, PDF document
BACKGROUND: Hodgkin lymphoma (HL) survivors are at increased risk of second malignancies, but few studies have assessed colorectal cancer (CRC) risk after HL treatment. We assessed long-term, subsite-specific CRC risk associated with specific radiation fields and chemotherapy regimens.
METHODS: In a Dutch cohort of 3121 5-year HL survivors treated between 1965 and 1995, subsite-specific CRC incidence was compared with general population rates. Treatment effects were quantified by Cox regression analyses.
RESULTS: After a median follow-up of 22.9 years, 55 patients developed CRC. The standardized incidence ratios (SIR) was 2.4-fold increased (95% confidence interval (95%CI) 1.8-3.2), leading to 5.7 excess cases per 10 000 patient-years. Risk was still increased 30 years after HL treatment (SIR: 2.8; 95%CI: 1.6-4.6). The highest (SIR: 6.5, 95%CI: 3.3-11.3) was seen for transverse colon cancer (15.0 (95%CI: 4.3-40.8) after inverted-Y irradiation). A prescribed cumulative procarbazine dose >4.2 g m(-2) was associated with a 3.3-fold higher CRC risk (95%CI: 1.8-6.1) compared to treatment without procarbazine. Patients receiving >4.2 g m(-2) procarbazine and infradiaphragmatic radiotherapy had a hazard ratio of 6.8 (95%CI: 3.0-15.6) compared with patients receiving neither treatment, which is significantly higher than an additive joint effect (Padditivity=0.004).
CONCLUSIONS: Colorectal cancer surveillance should be considered for HL survivors who received Infradiaphragmatic radiotherapy and a high cumulative procarbazine dose.
Original language | English |
---|---|
Journal | B J C |
Volume | 117 |
Issue number | 3 |
Pages (from-to) | 306-314 |
Number of pages | 9 |
ISSN | 0007-0920 |
DOIs | |
Publication status | Published - 25 Jul 2017 |
- Adult, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Colon, Colorectal Neoplasms, Diaphragm, Doxorubicin, Female, Follow-Up Studies, Hodgkin Disease, Humans, Male, Mechlorethamine, Middle Aged, Neoplasms, Radiation-Induced, Neoplasms, Second Primary, Netherlands, Prednisone, Procarbazine, Rectum, Risk Factors, Survivors, Vinblastine, Vincristine, Young Adult, Journal Article
Research areas
Number of downloads are based on statistics from Google Scholar and www.ku.dk
ID: 185405029